Treatment of myeloma bone disease: When, how often, and for how long?
The landscape of MM has changed dramatically in recent years. Several new and more effective treatments have been introduced that not only makes patients live longer but also brings them into a deeper remission. This makes the potential total exposure of bone protective treatment much higher but per...
Saved in:
| Main Authors: | Michael Tveden Gundesen, Fredrik Schjesvold, Thomas Lund |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of Bone Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137425000211 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of bone complications in multiple myeloma patients
by: V. V. Ptushkin
Published: (2022-11-01) -
Differences in interactions with the bone microenvironment between solid tumors and multiple myeloma: pathogenetic aspects. Possibilities and effectiveness of osteomodifying agents in multiple myeloma
by: A. V. Snegovoy, et al.
Published: (2021-04-01) -
Dynamic changes in γδT cells and bone resorption markers after zoledronic acid in multiple myeloma: A prospective study
by: Chao-Hung Wei, et al.
Published: (2025-07-01) -
Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events
by: Amman Bhasin, et al.
Published: (2025-02-01) -
Successful rapid desensitization to zoledronic acid in a multiple myeloma patient
by: Federico Spataro, et al.
Published: (2025-03-01)